SARomics Biostructures

Executive Summary

SARomics Biostructures is a Swedish structural biology services company founded in 2006, specializing in protein structure determination, fragment-based screening, and structure-based lead optimization for drug discovery. Leveraging its proximity to the MAX IV synchrotron, SARomics offers advanced crystallography and NMR services to global pharmaceutical and biotech clients. As a private, service-based firm, its growth depends on securing recurring contracts and expanding its technological capabilities. The company benefits from the increasing demand for outsourced structural biology to accelerate drug development, but faces competition from larger CROs. With no disclosed funding rounds or valuation, SARomics remains a niche player in the proteomics and antibodies space.

Upcoming Catalysts (preview)

• Q3 2026New strategic partnership with a top-20 pharma company for fragment-based screening60% success
• Q4 2026Expansion of services to include cryo-EM capabilities50% success
• Q1 2027Announcement of a multi-year contract extension with existing key client70% success